Chemistry co-founder: “more talented founders than ever” are moving into healthcare | Term Sheet

Term Sheet Podcast Summary: Christina Shen on Chemistry Ventures & the Future of VC

Key Concepts:

• Chemistry Ventures: A new early-stage venture capital firm founded by Christina Shen, Mark Goldberg, and Ethan Kerszwell.
• League Tables in Venture Capital: The ranking of VC firms based on performance; the discussion centers on a potential shift in these rankings due to the AI platform shift.
• AI & Healthcare Convergence: The increasing investment and potential for disruption in the healthcare industry through the application of Artificial Intelligence.
• Fund Size & Strategy: The correlation between the size of a VC fund and its investment approach, with a focus on the benefits of dedicated early-stage funds.
• Founder Chemistry: The importance of interpersonal dynamics and trust between co-founders for startup success.
• Quality of Revenue: A critical metric for evaluating startups, moving beyond simple ARR (Annual Recurring Revenue) to assess sustainability and customer value.
• Computer Use (AI Agents): The emerging potential of AI agents to automate tasks in legacy industries, particularly in back-office operations.

I. Elon Musk, AI Mergers & the Mega-IPO Era

The podcast begins with a discussion of Elon Musk’s merging of SpaceX, X (formerly Twitter), and XAI. While seemingly unconventional, it’s presented as consistent with Musk’s strategy of finding synergies between different ventures. The core argument is that this move signals the impending “era of the mega AI IPOs,” with potential trillion-dollar valuations, unlike anything previously seen. This sets the stage for a broader conversation about venture capital and the evolving landscape of AI investment.

II. Kleiner Perkins Turnaround & the Resilience of Tech Firms

A recent feature on Kleiner Perkins, a historically significant VC firm, is highlighted. The firm has undergone an eight-year turnaround, defying the typical “die young” nature of tech companies. This serves as a counterpoint to the rapid churn often seen in the industry and suggests the possibility of reinvention even for established players.

III. Interview with Christina Shen: Founding Chemistry Ventures

The core of the podcast is an interview with Christina Shen, co-founder and managing partner of Chemistry Ventures.

• Leaving Andreessen Horowitz (a16z): Shen explains her departure from a16z wasn’t a pre-planned move but a confluence of factors: the opportunity to partner with trusted friends (Mark Goldberg and Ethan Kerszwell), a belief in the need for a shift in venture league tables, and the potential for a dedicated early-stage fund to deliver outlier returns. She emphasizes the timing was right, coinciding with the AI platform shift creating shorter investment cycles.
• Fund Size & Focus: Chemistry Ventures intentionally raised a $350 million fund, prioritizing a focused early-stage strategy (seed to Series B, $3-30 million investments). This allows them to provide significant support and attention to each portfolio company, fostering a strong partnership. The fund size was determined through a “triangulation” of desired investment volume (30-40 companies) and the ability to comfortably fund both seed and Series A rounds.
• Brand & Founder Relationships: Shen argues that the brand of the investor is becoming increasingly important, with founders prioritizing personal connections and trust over the prestige of a large firm. She notes that building her own brand with Chemistry Ventures has expanded her network and deal flow. A key tenet is that founders want partners who will consistently advocate for their success, even years down the line.
• The "Peanut Buttering" Problem: Shen describes the challenge of larger funds spreading their resources too thinly across numerous portfolio companies, diminishing the value they can provide to each. Chemistry Ventures aims to avoid this by maintaining a smaller, more focused portfolio.
• Fundraising Experience: Chemistry Ventures benefited from being “first in the wave” of new firms launched by talent leaving larger funds, attracting strong LP (Limited Partner) interest due to the strength of the founding partnership.

IV. AI & Healthcare: Opportunities & Risks

Shen discusses Chemistry Ventures’ growing interest in the intersection of AI and healthcare.

• Why Healthcare Now? She believes AI is particularly well-suited to address inefficiencies in the healthcare system, particularly in labor-intensive back-office tasks. The rise of consumer health and a desire for greater control over healthcare decisions are also driving investment.
• Areas of Focus: Shen highlights opportunities in automating back-office processes, consumer healthcare solutions, and leveraging AI to improve data analysis and drug development.
• Areas of Caution: She cautions against direct displacement of doctors, emphasizing the continued importance of human expertise. She also expresses concern about diligence on AI healthcare startups and the potential for a bubble burst, given the rapid influx of capital.
• Quality of Revenue: Shen stresses the importance of evaluating the quality of revenue, moving beyond simple ARR to understand customer value and long-term sustainability. She emphasizes the need to determine if a product is a core component of a customer’s workflow (“number one or number two”).

V. The Future of Venture & the "Reckoning"

• The Changing League Tables: Shen predicts ongoing shifts in the venture capital landscape, with the emergence of new players and the potential for established firms to fall behind.
• The Role of Computer Use (AI Agents): She forecasts that 2026 will be the year AI agents (“computer use”) have a significant impact on automating tasks in legacy industries, particularly in areas with limited software integration.
• The Importance of Trust & Chemistry: Shen reiterates the critical role of trust and strong interpersonal dynamics between co-founders. She advises founders to prioritize alignment on their long-term vision and to trust their gut instincts.
• Co-founder Breakups: She acknowledges the risk of co-founder conflict and emphasizes the importance of clear division of labor, shared vision, and open communication.

Notable Quotes:

• “We’re backing people and we’re backing people who have a sparkle of an idea, great chemistry between them and a passion for what they’re doing.” – Christina Shen
• “I think the league tables need to change for venture.” – Christina Shen
• “I think it's okay that some companies have really high top of funnel from great consumers trying their products and they might turn out and then there's some stable base.” – Christina Shen
• “Trust your gut. I mean, I think everyone's intuition is generally right.” – Christina Shen

VI. Conclusion

The podcast highlights a shift in the venture capital landscape, driven by the AI revolution and a growing emphasis on founder-investor relationships. Chemistry Ventures represents a new guard, prioritizing focused early-stage investment, strong partnerships, and a commitment to supporting founders throughout their journey. The discussion underscores the importance of adaptability, trust, and a willingness to challenge conventional wisdom in this rapidly evolving environment. The key takeaway is that in the age of AI, speed, alignment, and a belief in the potential of founders will be crucial for success.